A London-based startup, Poolbeg Pharma, is set to trial POLB 001 at six NHS hospitals, aiming to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients.
The drug is called POLB 001
Jun 14, 2026
06:07 pm
What's the storyPoolbeg Pharma, a London-based start-up, is gearing up to test its novel oral drug POLB 001.
The medication is designed to make blood cancer treatment safer by preventing cytokine release syndrome (CRS).
Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
Amplia eyes major role in new cancer drug frontier
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Groundbreaking new NHS treatment sees patients go into remission
New antibody may boost KRAS-targeted lung cancer treatment after resistance emerges
BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
Even accounting for the share's doubling in the year-to-date, the valuation still looks modest relative to where the company is…
Pioneering drug can halt advance of multiple myeloma for three times as long as standard treatments
It sneaks toxic drugs inside cancer cells to hit them hard while minimising side-effects.
One early adopter describes how he was in remission ‘within the first two or three weeks’ after the treatment
New laws will let hospitals create personalised treatments on-site, cutting delays and improving outcomes for critically ill…
England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer therapy…
